{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T04:52:04Z","timestamp":1787028724007,"version":"build-2736575974"},"reference-count":64,"publisher":"MDPI AG","issue":"3","license":[{"start":{"date-parts":[[2019,9,4]],"date-time":"2019-09-04T00:00:00Z","timestamp":1567555200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JoF"],"abstract":"<jats:p>Terbinafine has proved to treat numerous fungal infections, including onychomycosis, successfully. Due to its liver metabolization and dependency on the cytochrome P450 enzyme complex, undesirable drug interaction are highly probable. Additionally to drug interactions, the treatment is long, rising the chances of the appearance of side effects and abandonment. Pharmacokinetic data suggest that terbinafine maintains a fungicidal effect within the nail up to 30 weeks after its last administration, which has aroused the possibility of a pulse therapy to reduce the side effects while treating onychomycosis. This study\u2019s goal was to evaluate the effectiveness of three different oral terbinafine regimens in treating onychomycosis due to dermatophytes. Sixty-three patients with onychomycosis were sorted by convenience in three different groups. Patients from group 1 received the conventional terbinafine dose (250 mg per day for 3 months). Group 2 received a monthly week-long pulse-therapy dose (500 mg per day for 7 days a month, for 4 months) and group 3 received a 500 mg\/day dose for 7 days every 3 months, totaling four treatments. There were no statistical differences regarding the effectiveness or side effects between the groups. Conclusion: A quarterly terbinafine pulse regimen can be a possible alternative for treating onychomycosis caused by dermatophytes.<\/jats:p>","DOI":"10.3390\/jof5030082","type":"journal-article","created":{"date-parts":[[2019,9,5]],"date-time":"2019-09-05T03:22:36Z","timestamp":1567653756000},"page":"82","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["A Week of Oral Terbinafine Pulse Regimen Every Three Months to Treat all Dermatophyte Onychomycosis"],"prefix":"10.3390","volume":"5","author":[{"given":"Anarosa B.","family":"Sprenger","sequence":"first","affiliation":[{"name":"Santa Casa de Curitiba Hospital, Clinic of Diseases and Surgery of the Nail Apparatus, Department of Dermatology, Pra\u00e7a Rui Barbosa, 694, 80.010-030 Curitiba, Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katia Sheylla Malta","family":"Purim","sequence":"additional","affiliation":[{"name":"Hospital de Cl\u00ednicas de Curitiba\u2014Universidade Federal do Paran\u00e1 (UFPR), Clinic of Dermatology, Rua General Carneiro, 181, 80.060-900 Curitiba, Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fl\u00e1via","family":"Sprenger","sequence":"additional","affiliation":[{"name":"Univerdidade Federal do Paran\u00e1 (UFPR), Rua General Carneiro, 181, 80.060-900 Curitiba, Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7034-2418","authenticated-orcid":false,"given":"Fl\u00e1vio","family":"Queiroz-Telles","sequence":"additional","affiliation":[{"name":"Hospital de Cl\u00ednicas de Curitiba\u2014Paran\u00e1 Federal University (UFPR), Department of Public Health, Rua General Carneiro, 181, 80.060-900 Curitiba, Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2019,9,4]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"776","DOI":"10.1016\/0190-9622(90)70286-Q","article-title":"History of antifungals","volume":"23","author":"Smith","year":"1990","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_2","first-page":"1350","article-title":"Oral treatment of onychomycosis of the toe nails; comparison of cost effectiveness of griseofulvin, itraconazole, ketoconazole and terbinafine","volume":"139","author":"Neumann","year":"1995","journal-title":"Ned. Tijdschr. Geneeskd."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/S1130-1406(05)70004-8","article-title":"Fungal infection of the feet in soccer players and non-athlete individuals","volume":"22","author":"Purim","year":"2005","journal-title":"Rev. Iberoam. Micol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1590\/S0365-05962009000500020","article-title":"Feet dermatophytosis in soccer player","volume":"84","author":"Purim","year":"2009","journal-title":"An. Braz. Dermatol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1177\/1203475417716362","article-title":"Onychomycosis in the 21st Century: An Update on Diagnosis, Epidemiology, and Treatment","volume":"21","author":"Gupta","year":"2017","journal-title":"J. Cutan. Med. Surg."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1016\/j.jaad.2017.09.030","article-title":"Weight change and risk of onychomycosis: A nationwide cohort study in Korea","volume":"78","author":"Ha","year":"2018","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1159\/000433473","article-title":"Network Meta-Analysis of Onychomycosis Treatments","volume":"1","author":"Gupta","year":"2015","journal-title":"Skin Appendage Disord."},{"key":"ref_8","first-page":"59","article-title":"Analysis of genetic polymorphism of the HLA-B and HLA-DR loci in patients with dermatophytic onychomycosis and in their first-degree relatives","volume":"103","author":"Granados","year":"2012","journal-title":"Actas Dermosifiliogr."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1159\/000446444","article-title":"Role of HLA-DR Alleles to Increase Genetic Susceptibility to Onychomycosis in Nail Psoriasis","volume":"2","author":"Granados","year":"2016","journal-title":"Skin Appendage Disord."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1007\/s11046-016-0046-z","article-title":"Genetic Predictors of Susceptibility to Dermatophytoses","volume":"182","year":"2017","journal-title":"Mycopathologia"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1177\/1203475417745827","article-title":"Onychomycosis and Chronic Fungal Disease: Exploiting a Commensal Disguise to Stage a Covert Invasion","volume":"22","author":"Gupta","year":"2018","journal-title":"J. Cutan. Med. Surg."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1016\/j.cpm.2016.02.001","article-title":"Onychomycosis: Evaluation, Treatment Options, Managing Recurrence, and Patient Outcomes","volume":"33","author":"Vlahovic","year":"2016","journal-title":"Clin. Podiatr. Med. Surg."},{"key":"ref_13","unstructured":"Lipner, S.R., and Scher, R.K. (2019). Part I: Onychomycosis: Clinical Overview and Diagnosis. J. Am. Acad. Dermatol."},{"key":"ref_14","first-page":"213","article-title":"The asymmetric gait toenail unit sign","volume":"10","author":"Zaias","year":"2012","journal-title":"Skinmed"},{"key":"ref_15","first-page":"217","article-title":"Asymmetric gait nail unit syndrome: The most common worldwide toenail abnormality and onychomycosis","volume":"12","author":"Zaias","year":"2014","journal-title":"Skinmed"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1590\/S0365-05962010000500009","article-title":"Dermatophytes- Host-pathogen interaction and antifungal resistance","volume":"85","author":"Peres","year":"2010","journal-title":"An. Braz. Dermatol."},{"key":"ref_17","doi-asserted-by":"crossref","unstructured":"Gupta, A.K., Foley, K.A., Mays, R.R., Shear, N.H., and Piguet, V. (2019). Monotherapy for toenail onychomycosis: A systematic review and network meta-analysis. Br. J. Dermatol.","DOI":"10.1111\/bjd.18155"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1007\/s11046-016-0045-0","article-title":"New Antifungal Agents and New Formulations Against Dermatophytes","volume":"182","author":"Gupta","year":"2017","journal-title":"Mycopathologia"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1111\/pde.13561","article-title":"Onychomycosis in children: Safety and efficacy of antifungal agents","volume":"35","author":"Gupta","year":"2018","journal-title":"Pediatr. Dermatol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1001\/jama.2017.20160","article-title":"Oral Medications to Treat Toenail Fungal Infection","volume":"319","author":"Hawke","year":"2018","journal-title":"JAMA"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1590\/abd1806-4841.20132018","article-title":"Treatment of superficial mycoses: Review. Part II","volume":"88","author":"Dias","year":"2013","journal-title":"An. Braz. Dermatol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"319","DOI":"10.2165\/00019053-200220050-00003","article-title":"Cost effectiveness of oral terbinafine (Lamisil) compared with oral fluconazole (Diflucan) in the treatment of patients with toenail onychomycosis","volume":"20","author":"Salo","year":"2002","journal-title":"Pharmacoeconomics"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1111\/j.1365-2230.1989.tb00904.x","article-title":"Clinical pharmacokinetics of terbinafine (Lamisil)","volume":"14","author":"Jensen","year":"1989","journal-title":"Clin. Exp. Dermatol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1111\/j.1365-2230.1995.tb01353.x","article-title":"Nail incorporation kinetics of terbinafine in onychomycosis patients","volume":"20","author":"Schatz","year":"1995","journal-title":"Clin. Exp. Dermatol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/S0190-9622(98)70483-9","article-title":"Pharmacokinetics and pharmacology of terbinafine and itraconazole","volume":"38","author":"Leyden","year":"1998","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1016\/j.jaad.2005.04.055","article-title":"Pulse versus continuous terbinafine for onychomycosis: A randomized, double-blind, controlled trial","volume":"53","author":"Warshaw","year":"2005","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1111\/j.1439-0507.2008.01531.x","article-title":"Treatment of dermatophyte onychomycosis with three pulses of terbinafine (500 mg day for a week)","volume":"52","author":"Takahata","year":"2009","journal-title":"Mycoses"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"262","DOI":"10.4103\/0378-6323.16619","article-title":"An open randomized comparative study of oral itraconazole pulse and terbinafine pulse in the treatment of onychomycosis","volume":"71","author":"Mishra","year":"2005","journal-title":"Indian J. Dermatol. Venereol. Leprol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1001\/archderm.140.6.691","article-title":"The successful treatment of Trichophyton rubrum nail bed (distal subungual) onychomycosis with intermittent pulse-dosed terbinafine","volume":"140","author":"Zaias","year":"2004","journal-title":"Arch. Dermatol."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/j.cmpb.2013.05.023","article-title":"Privacy-preserving Kruskal-Wallis test","volume":"112","author":"Guo","year":"2013","journal-title":"Comput. Methods Programs Biomed."},{"key":"ref_31","doi-asserted-by":"crossref","unstructured":"Gupta, A.K., and Stec, N. (2019). Recent advances in therapies for onychomycosis and its management. F1000Research, 8.","DOI":"10.12688\/f1000research.18646.1"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1016\/j.mycmed.2014.10.004","article-title":"New clinical classification for onychomycoses","volume":"24","author":"Baran","year":"2014","journal-title":"J. Mycol. Med."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1111\/j.1365-2230.1989.tb00908.x","article-title":"Clinical efficacy and tolerability of terbinafine (Lamisil)\u2014A new topical and systemic fungicidal drug for treatment of dermatomycoses","volume":"14","author":"Villars","year":"1989","journal-title":"Clin. Exp. Dermatol."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1016\/j.clindermatol.2013.06.011","article-title":"Therapies for the treatment of onychomycosis","volume":"31","author":"Gupta","year":"2013","journal-title":"Clin. Dermatol."},{"key":"ref_35","first-page":"253","article-title":"Clinical Insights About Onychomycosis and Its Treatment: A Consensus","volume":"17","author":"Hanna","year":"2018","journal-title":"J. Drugs Dermatol."},{"key":"ref_36","doi-asserted-by":"crossref","unstructured":"Gupta, A.K., Mays, R.R., Versteeg, S.G., Piraccini, B.M., Takwale, A., Shemer, A., Babaev, M., Grover, C., Di Chiacchio, N.G., and Taborda, P.R.O. (2018). Global perspectives for the management of onychomycosis. Int. J. Dermatol., 1\u201312.","DOI":"10.1111\/ijd.14346"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1067\/mjd.2001.114565","article-title":"Terbinafine-induced subacute cutaneous lupus erythematosus","volume":"44","author":"Bonsmann","year":"2001","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_38","doi-asserted-by":"crossref","unstructured":"Cerci, F., Carvalho, M., and Nihi, F. (2016). Erythrodermic psoriasis following terbinafine use. J. Am. Acad. Dermatol., 74.","DOI":"10.1016\/j.jaad.2016.02.971"},{"key":"ref_39","first-page":"785","article-title":"Drug-induced Rowell syndrome, a rare and difficult to manage disease: A case report","volume":"15","author":"Branisteanu","year":"2018","journal-title":"Exp. Ther. Med."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"e12617","DOI":"10.1111\/dth.12617","article-title":"Acute generalized exanthematous pustulosis due to terbinafine","volume":"31","author":"Ross","year":"2018","journal-title":"Dermatol. Ther."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1067\/mjd.2002.126823","article-title":"SNH Drug interactions: Proteins, pumps, and P-450s","volume":"47","author":"Shapiro","year":"2002","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"1078","DOI":"10.1053\/j.gastro.2016.12.016","article-title":"Association of Liver Injury From Specific Drugs, or Groups of Drugs, With Polymorphisms in HLA and Other Genes in a Genome-Wide Association Study","volume":"152","author":"Nicoletti","year":"2017","journal-title":"Gastroenterology"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1590\/abd1806-4841.20131781","article-title":"General aspects of drug interactions with systemic antifungals in a retrospective study sample","volume":"88","author":"Schmitt","year":"2013","journal-title":"An. Braz. Dermatol."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1080\/17425255.2018.1461834","article-title":"Common drug-drug interactions in antifungal treatments for superficial fungal infections","volume":"14","author":"Gupta","year":"2018","journal-title":"Expert Opin. Drug Metab. Toxicol."},{"key":"ref_45","doi-asserted-by":"crossref","unstructured":"Monod, M., and Mehul, B. (2019). Recent Findings in Onychomycosis and Their Application for Appropriate Treatment. J. Fungi, 5.","DOI":"10.3390\/jof5010020"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1111\/j.1468-3083.2008.03036.x","article-title":"The use of an intermittent terbinafine regimen for the treatment of dermatophyte toenail onychomycosis","volume":"23","author":"Gupta","year":"2009","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"ref_47","doi-asserted-by":"crossref","unstructured":"Christenson, J., Peterson, G., Naunton, M., Bushell, M., Kosari, S., Baby, K., and Thomas, J. (2018). Challenges and Opportunities in the Management of Onychomycosis. J. Fungi, 4.","DOI":"10.3390\/jof4030087"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"401","DOI":"10.2165\/00019053-200119040-00007","article-title":"Cost effectiveness of continuous terbinafine compared with intermittent itraconazole in the treatment of dermatophyte toenail onychomycosis: An analysis of based on results from the L.I.ON. study. Lamisil versus Itraconazole in Onychomycosis","volume":"19","author":"Jansen","year":"2001","journal-title":"Pharmacoeconomics"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1111\/j.1365-2133.2011.10660.x","article-title":"A randomized, placebo- and active-controlled, parallel-group, multicentre, investigator-blinded study of four treatment regimens of posaconazole in adults with toenail onychomycosis","volume":"166","author":"Elewski","year":"2012","journal-title":"Br. J. Dermatol."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"S2","DOI":"10.12788\/j.sder.0014","article-title":"The Epidemiology, Etiology, and Pathophysiology of Onychomycosis","volume":"32","author":"Scher","year":"2013","journal-title":"Semin. Cutan. Med. Surg."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"1219","DOI":"10.1016\/j.jaad.2010.09.730","article-title":"Onychomycosis: A proposed revision of the clinical classification","volume":"65","author":"Hay","year":"2011","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1016\/j.jaad.2018.05.1260","article-title":"Part II: Onychomycosis: Treatment and Prevention of Recurrence","volume":"80","author":"Lipner","year":"2019","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"50","DOI":"10.23736\/S0392-0488.18.06001-7","article-title":"Evidence for biofilms in onychomycosis","volume":"154","author":"Gupta","year":"2019","journal-title":"Giornale Italiano di Dermatologia e Venereologia"},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1111\/j.1529-8019.2007.00109.x","article-title":"Toenail onychomycosis: Current and future treatment options","volume":"20","author":"Finch","year":"2007","journal-title":"Dermatol. Ther."},{"key":"ref_55","first-page":"1","article-title":"Dermatophyte Onychomycosis: The Active Invasion of a Normal Nail Unit versus the Colonization of an Existing Abnormal Nail Unit by Environmental Fungus","volume":"X","author":"Zaias","year":"2019","journal-title":"SKINmed"},{"key":"ref_56","unstructured":"World Health Organization (2019). Life Spectancy Situation, World Health Organization. Available online: https:\/\/www.who.int\/gho\/mortality_burden_disease\/life_tables\/situation_trends_text\/en\/."},{"key":"ref_57","doi-asserted-by":"crossref","unstructured":"Piraccini, B., and Alessandrini, A. (2015). Onychomycosis: A Review. J. Fungi, 1.","DOI":"10.3390\/jof1010030"},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/j.clindermatol.2017.10.007","article-title":"Hair and nail diseases in the mature patient","volume":"36","author":"Maddy","year":"2018","journal-title":"Clin. Dermatol."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1007\/s40257-018-0403-4","article-title":"A Practical Guide to Curing Onychomycosis: How to Maximize Cure at the Patient, Organism, Treatment, and Environmental Level","volume":"20","author":"Gupta","year":"2019","journal-title":"Am. J. Clin. Dermatol."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1016\/j.jaad.2003.07.011","article-title":"Modulation of linear nail growth to treat diseases of the nail","volume":"50","author":"Geyer","year":"2004","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"51","DOI":"10.3109\/09546639009089035","article-title":"Nail Matrix Kinetics of Oral Terbinafine in Onychomycosis and Normal Cells","volume":"1","author":"Finlay","year":"1990","journal-title":"J. Dermatol. Treat."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1111\/j.1365-2133.2007.07974.x","article-title":"A multicentre, randomized, controlled study of the efficacy, safety and cost-effectiveness of a combination therapy with amorolfine nail lacquer and oral terbinafine compared with oral terbinafine alone for the treatment of onychomycosis with matrix involvement","volume":"157","author":"Baran","year":"2007","journal-title":"Br. J. Dermatol."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1016\/j.jaad.2019.01.032","article-title":"Pharmacy Costs of Medications for the Treatment of Onychomycosis in the United States","volume":"81","author":"Yang","year":"2019","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"e105","DOI":"10.1016\/j.jaad.2018.11.010","article-title":"Mobile Phone Reminders for Onychomycosis Medication Adherence","volume":"80","author":"Lin","year":"2018","journal-title":"J. Am. Acad. Dermatol."}],"container-title":["Journal of Fungi"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2309-608X\/5\/3\/82\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T13:16:38Z","timestamp":1760188598000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2309-608X\/5\/3\/82"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,9,4]]},"references-count":64,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2019,9]]}},"alternative-id":["jof5030082"],"URL":"https:\/\/doi.org\/10.3390\/jof5030082","relation":{},"ISSN":["2309-608X"],"issn-type":[{"value":"2309-608X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,9,4]]}}}